Literature DB >> 10629033

p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines.

O N Aurelio1, X T Kong, S Gupta, E J Stanbridge.   

Abstract

A bidirectional expression vector that allowed equal transcription of cloned wild-type and mutant p53 cDNAs from the same vector was developed. The vector was transfected into CaLu 6 lung carcinoma cells or Saos-2 osteosarcoma cells. All p53 mutants examined were recessive to wild-type p53 transactivation of p21(WAF1/CIP1) but dominant-negative for transactivation of Bax. An examination of effects on growth arrest and apoptotic pathways indicated that all mutants were recessive to wild type for growth arrest but only three of seven mutants were dominant negative for induction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10629033      PMCID: PMC85193          DOI: 10.1128/MCB.20.3.770-778.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  50 in total

1.  Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation.

Authors:  P Hinds; C Finlay; A J Levine
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

2.  The p53 proto-oncogene can act as a suppressor of transformation.

Authors:  C A Finlay; P W Hinds; A J Levine
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

Review 3.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

4.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

Authors:  L Raycroft; H Y Wu; G Lozano
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

5.  Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents.

Authors:  A J Fornace; D W Nebert; M C Hollander; J D Luethy; M Papathanasiou; J Fargnoli; N J Holbrook
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

6.  Primary structure polymorphism at amino acid residue 72 of human p53.

Authors:  G J Matlashewski; S Tuck; D Pim; P Lamb; J Schneider; L V Crawford
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

7.  A variation in the structure of the protein-coding region of the human p53 gene.

Authors:  V L Buchman; P M Chumakov; N N Ninkina; O P Samarina; G P Georgiev
Journal:  Gene       Date:  1988-10-30       Impact factor: 3.688

8.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

9.  Presence of a potent transcription activating sequence in the p53 protein.

Authors:  S Fields; S K Jang
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

10.  Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest.

Authors:  K M Ryan; K H Vousden
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

View more
  15 in total

1.  Single nucleotide polymorphism seeking long term association with complex disease.

Authors:  Brian W Kirk; Matthew Feinsod; Reyna Favis; Richard M Kliman; Francis Barany
Journal:  Nucleic Acids Res       Date:  2002-08-01       Impact factor: 16.971

2.  How many mutant p53 molecules are needed to inactivate a tetramer?

Authors:  Wan Mui Chan; Wai Yi Siu; Anita Lau; Randy Y C Poon
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

3.  Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway.

Authors:  Ricardo E Perez; Chad D Knights; Geetaram Sahu; Jason Catania; Vamsi K Kolukula; Daniel Stoler; Adolf Graessmann; Vasily Ogryzko; Michael Pishvaian; Christopher Albanese; Maria Laura Avantaggiati
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

4.  Effects of febrile temperature on adenoviral infection and replication: implications for viral therapy of cancer.

Authors:  Stephen H Thorne; Gabriel Brooks; Yeun-Ling Lee; Tina Au; Lawrence F Eng; Tony Reid
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.

Authors:  Xiaoyang Li; Yuri K Peterson; Elizabeth S Inks; Richard A Himes; Jiaying Li; Yingjie Zhang; Xiujie Kong; C James Chou
Journal:  J Med Chem       Date:  2018-03-09       Impact factor: 7.446

6.  p53 directly suppresses BNIP3 expression to protect against hypoxia-induced cell death.

Authors:  Xi Feng; Xing Liu; Wei Zhang; Wuhan Xiao
Journal:  EMBO J       Date:  2011-07-26       Impact factor: 11.598

Review 7.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

8.  Blockage of NF-kappaB by IKKbeta- or RelA-siRNA rather than the NF-kappaB super-suppressor IkappaBalpha mutant potentiates adriamycin-induced cytotoxicity in lung cancer cells.

Authors:  Wenshu Chen; Xia Wang; Lang Bai; Xiaomin Liang; Jianguo Zhuang; Yong Lin
Journal:  J Cell Biochem       Date:  2008-10-01       Impact factor: 4.429

9.  Genetic modeling of Li-Fraumeni syndrome in zebrafish.

Authors:  John M Parant; Stephen A George; Joseph A Holden; H Joseph Yost
Journal:  Dis Model Mech       Date:  2010 Jan-Feb       Impact factor: 5.758

10.  Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.

Authors:  Chih-Jian Lih; David J Sims; Robin D Harrington; Eric C Polley; Yingdong Zhao; Michele G Mehaffey; Thomas D Forbes; Biswajit Das; William D Walsh; Vivekananda Datta; Kneshay N Harper; Courtney H Bouk; Lawrence V Rubinstein; Richard M Simon; Barbara A Conley; Alice P Chen; Shivaani Kummar; James H Doroshow; Paul M Williams
Journal:  J Mol Diagn       Date:  2015-11-18       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.